Ionis Pharmaceuticals
IONS
339 hedge funds and large institutions have $4.92B invested in Ionis Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 116 increasing their positions, 106 reducing their positions, and 53 closing their positions.
19% more call options, than puts
Call options by funds: $15.2M | Put options by funds: $12.8M
2.67% more ownership
Funds ownership: 89.03% → 91.7% (+2.7%)
9% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 106
6% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 53
3% less funds holding
Funds holding: 350 → 339 (-11)
12% less capital invested
Capital invested by funds: $5.59B → $4.92B (-$667M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$51.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$50.7M |
| 3 |
TBC
Tweedy, Browne Co
Stamford,
Connecticut
|
+$34.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.2M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$27.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$73.7M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$43.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$21.2M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$18M |
| 5 |
Goldman Sachs
New York
|
-$15.5M |
IONS Hedge Fund Activity: Q4 2022 in Review
339 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2022, worth a combined $4.92B — down 12% from $5.59B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of IONS and 50 opened new positions — a net loss of 3 holders — while 106 trimmed existing stakes and 116 added.
The largest buyer was OrbiMed, adding an estimated $51.5M. The largest seller was BVF Inc, cutting an estimated $73.7M.
- 339 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2022, down from 350 in Q3 2022.
- Funds reported $4.92B of Ionis Pharmaceuticals stock for Q4 2022, down 12% quarter-over-quarter.
- 50 funds opened new Ionis Pharmaceuticals positions in Q4 2022 and 53 closed out, a net change of -3 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2022 was OrbiMed, an estimated $51.5M added.
- The largest Ionis Pharmaceuticals seller in Q4 2022 was BVF Inc, an estimated $73.7M sold.
Based on aggregated 13F filings for Q4 2022.